Exhibit 10.2


 


FORM
OF SECOND AMENDED AND RESTATED EMPLOYMENT
AGREEMENT


 


This
Second Amended and Restated Employment Agreement (the “Agreement”), effective as of April 11, 2020 (the
“Effective Date”), is between Corbus Pharmaceuticals Holdings, Inc. (the “Company”)
and Barbara White (the “Executive”).


 


WITNESSETH:


 


WHEREAS,
the Executive has been employed by the Company as its Chief Medical Officer pursuant to the terms of an amended and restated employment
agreement dated April 11, 2018, as amended (the “Prior Employment Agreement”);


 


WHEREAS,
the Company desires to continue to employ the Executive as its Chief Medical Officer, and the Executive desires to accept such
continued employment, on the terms and conditions set forth in this Agreement; and


 


WHEREAS,
the Company and the Executive have mutually agreed that, as of the Effective Date, this Agreement shall amend, restate and replace
the Prior Employment Agreement.


 


NOW,
THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound
hereby, agree as follows:


 


	1.	EMPLOYMENT.
    Subject to the terms and conditions set forth herein, the Company hereby employs the Executive, and the Executive hereby accepts
    such employment by the Company commencing on the Effective Date.


 


	2.	SCOPE
    OF EMPLOYMENT. During the term of this Agreement, Executive shall hold the position of Chief Medical Officer and shall
    have those duties and responsibilities customarily associated with the title Chief Medical Officer plus any additional duties
    as may reasonably be assigned to her from time to time by the Company. The Executive shall report directly to the Chief Executive
    Officer. The Executive will devote her full time and best efforts to the business and affairs of the Company. The Executive
    shall be subject to and comply with the Company’s policies, procedures and approval practices as generally in effect
    at any time and from time to time. 


 


	3.	PREVIOUS
    OBLIGATIONS. The Executive represents that her employment by the Company and the performance of her duties on behalf
    of the Company does not, and shall not, breach any agreement that obligates the Executive to keep in confidence any trade
    secrets or confidential or proprietary information of any other party or to refrain from competing, directly or indirectly,
    with the business of any other party. The Executive shall not disclose to the Company any trade secrets or confidential or
    proprietary information of any other party.


 




    	 	 	 



     


    

 


	4.	COMPENSATION.
    As full compensation for all services to be rendered by Executive during the term of this Agreement, the Company will compensate
    the Executive as follows.


 


	 	4.1	Base
    Salary. The Company shall pay the Executive a base salary (the “Base Salary”) at the annualized
    rate of $439,000, which shall be subject to customary withholdings and authorized deductions and shall be payable in equal
    installments in accordance with the Company’s customary payroll practices in place from time to time. The Executive’s
    Base Salary shall be subject to review on at least an annual basis. The foregoing annualized rate will be effective for fiscal
    year 2020 and may be reevaluated by the Company’s Board of Directors for fiscal year 2021.


 


	 	4.2	Annual
    Bonus.


 


	 	(a)	The
    Executive will be eligible to participate in an annual executive bonus plan pursuant to which she may earn a bonus (“Bonus”)
    equal to up to 40% of her Base Salary (such maximum bonus may be referred to as the “Target Bonus”).


 


	 	(b)	Prior
    to the commencement of each calendar year the Company’s Board of Directors (the “Board”) will
    establish and approve the Target Bonus for such calendar year. Achievement of the Target Bonus will be based on the Executive
    meeting individual objectives and the Company meeting Company-wide objectives (collectively, the “Performance
    Criteria”). 


 


	 	(c)	The
    Board may, in its discretion, grant the Executive a Bonus in excess of the Target Bonus if the Performance Criteria are exceeded.


 


	 	(d)	Following
    the close of each calendar year but in no event later than January 30th, the Board will meet and determine the extent to which
    the Performance Criteria have been achieved for such year and the amount of the Bonus. Based on that determination, payment
    of the Bonus (if any) shall be made by March 15th.


 


	 	(e)	Notwithstanding
    the foregoing to the contrary (including all Performance Criteria being met), payment of the Bonus shall be at the discretion
    of the Board based on the financial condition of the Company.


 


	 	4.3	Benefits.
    During her employment and subject to any contribution therefore generally required of employees of the Company, the Executive
    shall be entitled to participate in any and all employee benefit plans from time to time in effect for executive employees
    of the Company generally. Such participation shall be subject to (i) the terms of the applicable plan documents, (ii) generally
    applicable policies of the Company and (iii) the discretion of the Board or any administrative or other committee provided
    for in or contemplated by such plan. The Company may alter, modify, add to or delete its employee benefit plans at any time
    as it, in its sole judgment, deems appropriate.


 




    	 	-2-	 



     


    

 


	 	4.4	Vacations
    and Holidays. During the term of her employment, the Executive shall be entitled to 15 paid days off per calendar
    year (none of which may be carried over from one year to the next, except as otherwise required by applicable law) as well
    as those paid public holidays provided for in the Company’s standard policies, as they may be amended from time to time.


 


	 	4.5	Changes
    to Compensation. After the Term (as defined below), the Company may, at its sole discretion, change the terms of the
    Executive’s compensation (other than the terms and conditions of outstanding options or other awards under the Corbus
    Pharmaceuticals Holdings, Inc. 2014 Equity Compensation Plan (the “2014 Plan”) which shall continue
    to be governed by the applicable award agreements and the 2014 Plan). The Company shall give the Executive at least 14 days’
    prior written notice of any such changes.


 


	5.	EXPENSES.
The Executive shall be entitled to reimbursement by the Company for all necessary and reasonable travel, entertainment and other
business expenses incurred by her in connection with her duties hereunder. The Company shall reimburse the Executive for all such
expenses upon presentation of an itemized account and appropriate supporting documentation, all in accordance with the Company’s
generally applicable policies as in effect from time to time.

	 	 
	6.	CONFIDENTIALITY.

         

        6.1
        Definition. During the term of her employment, the Executive will have access to the Company’s confidential
        business information (the “Confidential Information”). Confidential Information means
        all trade secrets, know-how, show-how, theories, technical, operating, financial and other business information relating
        to the Company, its affiliates and each of their respective businesses or potential businesses, whether or not reduced
        to writing or other medium, and whether or not marked or labeled confidential, proprietary or the like, specifically including,
        without limitation, the following: inventions (including, without limitation, Work Product (as defined below)), designs,
        data, computer code, works of authorship, formulas, compounds, indications, techniques, ideas, discoveries, products and
        services under development, investor, customer and vendor information of any kind, marketing and business plans, pricing
        and profit margins, memoranda, notes, records, files, reports and other documentation, processes, business methods, improvements,
        modifications and creations, methodology, concepts, research, specifications, data processes, operations procedures, computer
        systems and software; provided, however, that Confidential Information shall not include information that is or becomes
        generally available to the public, unless such information has become generally available as a result of the Executive’s
        direct or indirect act or omission or as a result of the disclosure by any other person in violation of any contractual,
        legal or fiduciary obligation.




 






    	 	-3-	 



     


    

 


	 	6.2
        Use of Confidential Information. Subject to the other provisions of this Agreement, the Executive shall
        use Confidential Information only in the performance of the Executive’s duties for the Company. Subject to the other
        provisions of this Agreement, the Executive shall not use Confidential Information at any time (during or after the Executive’s
        employment) for the Executive’s personal benefit or in any manner adverse to the interests of the Company, its affiliates,
        or any of their respective investors and clients.

         

        6.3
        Protection and Non-Disclosure of Confidential Information. The Executive shall safeguard the Confidential
        Information by all reasonable steps and abide by all policies and procedures of the Company in effect from time to time
        regarding storage, copying, destroying, publication or posting, and handling of such Confidential Information, in whatever
        medium or format that Confidential Information takes. At all times during and after her employment by the Company, the
        Executive shall not, unless the Company expressly consents in advance in writing or unless otherwise permitted by this
        Agreement, disclose Confidential Information at any time except (i) to authorized Company personnel, or (ii) when required
        to do so by a court of law, a governmental agency, or an administrative or legislative body (each with jurisdiction to
        order the Executive to divulge, disclose or make accessible such information); provided that, the Executive shall give
        prompt written notice to the Company of such requirement and reasonably cooperate with any attempt by the Company and/or
        its affiliates to obtain a protective order or similar treatment. Notwithstanding the foregoing, nothing in this Agreement
        prohibits, limits, or otherwise interferes with the Executive’s protected rights under federal, state or local law
        to, without notice to the Company, (i) communicate or file a charge with a government regulator; (ii) participate in an
        investigation or proceeding conducted by a government regulator; or (iii) receive an award paid by a government regulator
        for providing information.

         

        6.4
        Return of Confidential Information. Upon request of the Company, the Executive will promptly (i) deliver
        to the Company all documents and other tangible media in the Executive’s possession or control that evidence, contain
        or reflect Confidential Information (including all copies, reproductions, digests, abstracts, analyses, and notes) and
        (ii) destroy any intangible materials that evidence, contain or reflect Confidential Information on equipment or media
        not owned by the Company.

         

        6.5
        Other Agreements. The Executive shall execute and abide by all confidentiality agreements which the Company
        reasonably requests the Executive to sign or abide by, whether those agreements are for the benefit of the Company, an
        affiliate of the Company, or an actual or a potential client thereof.

         

        6.6
        Defend Trade Secrets. The Executive acknowledges that the Executive shall not be held criminally or civilly
        liable under any federal or state trade secret law for the disclosure of a trade secret if (i) the Executive makes such
        disclosure in confidence to a federal, State, or local government official, either directly or indirectly, or to an attorney
        and such disclosure is made solely for the purpose of reporting or investigating a suspected violation of law, or (ii)
        the Executive makes such disclosure in a complaint or other document filed in a lawsuit or other proceeding if such filing
        is made under seal. Further, an individual who files a lawsuit for retaliation by an employer for reporting a suspected
        violation of law may disclose the employer’s trade secrets to the attorney and use the trade secret information
        in the court proceeding if the individual: (i) files any document containing the trade secret under seal; and (ii) does
        not disclose the trade secret, except pursuant to court order. Nothing contained herein will waive, limit or affect any
        rights of the Company under any applicable trade secrets laws, including Defend Trade Secrets Act of 2016, which will
        be enforceable separate and apart from this Agreement.




 






    	 	-4-	 



     


    

 


	 	7.
        ASSIGNMENT OF WORK PRODUCT.

         

        7.1
        Definitions. The following capitalized terms shall have the meanings assigned to them below:

         

        “Intellectual
        Property” means collectively all Work Product and all Intellectual Property Rights relating to all Work
        Product.

         

        “Intellectual
        Property Rights” means all copyrights, copyright registrations and copyright applications, trademarks, service
        marks, trade dress, trade names, trademark registrations and trademark applications, patents and patent applications,
        trade secret rights, and all other intellectual property rights and intellectual property interests existing, created
        or protectable under any intellectual property or other law of any nation.

         

        “Work
        Product” means any and all inventions, discoveries, works of authorship, developments, improvements, formulas,
        compounds, indications, techniques, concepts, data and ideas (whether or not patentable or registerable under patent,
        copyright, or similar statute) made, conceived, prepared, created, discovered, or reduced to practice by the Executive,
        either alone or jointly with others, during the period of her employment, that (i) result or relate to work performed
        by the Executive for the Company, (ii) are made by use of the equipment, supplies, facilities or Confidential Information
        of the Company, or are made, conceived or completed, wholly or in part, during hours in which the Executive is working
        for the Company, or (iii) are related to the business of the Company or the actual or demonstrably anticipated business
        of the Company.

         

        7.2
        Property of the Company. All Intellectual Property is and will be the sole property of the Company.

         

        7.3
        Copyrights; Assignment. The Executive agrees that all copyrightable materials that fall within the definition
        of Work Product, will be, to the maximum extent permitted by law, works-made-for-hire for the Company under copyright
        law, and to the extent not works-made-for-hire, the Executive hereby irrevocably assigns to the Company, without royalty
        or further consideration to the Executive, all right, title, and interest he may have, or may acquire, in and to all Intellectual
        Property.

         

        7.4
        Disclosure. The Executive will promptly disclose in writing all Work Product to the Company. The Executive
        agrees to keep adequate and current written records of all such Work Product, in the form of notes, sketches, drawings,
        electronic records and/or other reports, which records are, and will remain, the sole property of the Company and will
        be available to the Company at all times.




 






    	 	-5-	 



     


    

 


	 	7.5
        Execution of Documents. Whenever requested by the Company, both during the period of the Executive’s
        employment and thereafter, the Executive will promptly sign and deliver to the Company any and all applications, assignments
        and other documents that the Company considers necessary or desirable in order to: (a) assign, apply for, obtain, and
        maintain any Intellectual Property Rights in the United States and for other countries relating to any Work Product, (b)
        assign and convey to the Company or its designee the sole and exclusive right, title, and interest in and to all Intellectual
        Property, (c) provide evidence regarding the Intellectual Property that the Company considers necessary or desirable,
        and (d) confirm the Company’s ownership of the Intellectual Property, all without royalty or any other further consideration
        to the Executive.

         

        7.6
        Assistance to the Company. Whenever requested by the Company, both during the period of the Executive’s
        employment and thereafter, the Executive will assist the Company in assigning, obtaining, maintaining, defending, registering
        and from time to time enforcing, in any and all countries, the Company’s right to the Intellectual Property. This
        assistance may include, without limitation, testifying in a suit or other proceeding. If the Company requires assistance
        from the Executive after termination of her employment, other than assistance as set forth in Section 7.5, the Executive
        will be compensated for time actually spent in providing assistance at an hourly rate equivalent to her compensation at
        the time her employment was terminated together with her reasonable, actual out-of-pocket expenses incurred in providing
        such assistance, to the extent permitted by applicable law and/or court rules.

         

        7.7
        Power of Attorney. For use in the case that the Company cannot obtain the Executive’s signature on
        any document that the Company considers necessary or desirable in order to assign, apply for, prosecute, obtain, or enforce
        any Intellectual Property, whether due to the Executive’s non-cooperation, unavailability, or any other reason,
        the Executive hereby irrevocably designates and appoints the Company and each of its duly authorized officers and agents
        as her agent and attorney-in-fact to act for, and on the Executive’s behalf, to execute and file any such document
        and to do all other lawfully permitted acts to further the assignment, transfer to the Company, application, registration,
        prosecution, issuance, and enforcement of all Intellectual Property, with the same force and effect as if executed and
        delivered by the Executive.

         

        7.8
        Prior Inventions. The Executive represents that any inventions, prior works of authorship, discoveries,
        concepts or ideas, if any, to which the Executive presently has any right, title or interest, and which were previously
        conceived either wholly or in part by the Executive, and that the Executive desires to exclude from the operation of this
        Agreement are identified on Schedule A of this Agreement (each a “Prior Invention”).
        The Executive represents that the list contained in Schedule A is complete to the best of her knowledge. If during the
        Executive’s retention with the Company, the Executive incorporates a Prior Invention into a Company product, process
        or service or its use, the Executive shall be deemed to have automatically granted to the Company a nonexclusive, royalty-free,
        irrevocable, perpetual, worldwide license to make, have made, modify, display, perform sell and otherwise use such Prior
        Invention as part of or in connection with any Company product, process or service. The Executive shall not incorporate
        a Prior Invention into a Company product, process or service or its use without the Company’s prior written consent.




 






    	 	-6-	 



     


    

 


	 	8.
        NON-COMPETITION; NON-SOLICITATION.

         

        8.1
        Non-competition. To protect the Company’s legitimate interests in, among other things, the Company’s
        Confidential Information, trade secrets, and goodwill, during the Employment Period and the Restricted Period (as defined
        below), the Executive shall not, in any geographic location where within the two years prior to cessation of employment
        with the Company the Executive provided services to the Company or had a material presence or influence, directly or indirectly,
        whether as a partner, principal, shareholder, licensor, licensee, employee, officer, director, manager, agent, representative,
        advisor, promoter, associate, investor, or otherwise, assist in or engage in providing any services that the Executive
        provided to the Company during the prior two years, to a Competitive Business (as defined below). The geographic limitation
        as set forth in this Section 8.1 does not apply during the Employment Period, during which there is no geographic limitation
        to the restrictions as set forth in this Section 8.1.

         

        In
        furtherance of the foregoing, the Company will provide the Executive with the following:

         

        (a)   Subject to Sections 11.3 and 11.4, in the event that the Executive’s employment with the Company is terminated
        by the Company without Cause or by the Executive for Good Reason, during the Term (as defined below) other than during
        the Change in Control Period (as defined in subsection 8.1(b)), the Company shall pay to the Executive an amount equal
        to twelve months of her then current Base Salary under Section 4.1 above (less applicable withholdings and authorized
        deductions), to be paid in equal installments bimonthly in accordance with the Company’s customary payroll practices,
        commencing sixty (60) days following the date of termination of employment.

         

        (b)   Subject to Sections 11.3 and 11.4, in the event that the Executive’s employment is terminated by the Company
        without Cause or by the Executive for Good Reason, during the Term and within the 3 months immediately preceding or the
        12 months immediately following a Change in Control (as defined in Section 11.2) (each, the “Change in Control
        Period”), then in lieu of the payments set forth in subsection 8.1(a) above, the Company shall pay to the
        Executive an amount equal to eighteen (18) months of her then current Base Salary under Section 4.1 above (less applicable
        withholdings and authorized deductions), to be paid in equal installments bimonthly in accordance with the Company’s
        customary payroll practices, commencing sixty (60) days following the date of termination of employment. For avoidance
        of doubt, if such termination precedes a Change in Control and any payments or benefits have commenced pursuant to subsection
        8.1(a), such payments or benefits shall be taken into account for purposes of this subsection 8.1(b).




 






    	 	-7-	 



     


    

 


	 	The
        Executive has the right to consult with counsel prior to signing this Agreement, including this Section 8.1.

         

        The
        Executive shall not provide any services to any other person, company, entity or firm while the Executive is employed
        by the Company without the Company’s written consent and may not do anything that may result in an actual or perceived
        conflict of interest to the Company.

         

        During
        the Restricted Period, the Executive shall, upon the Company’s request, honestly, accurately, and completely provide
        the Company with the name of any prospective new employer or hiring entity that follows the Executive’s separation
        from the Company. During the Employment Period and the Restricted Period, the Executive shall, upon the Company’s
        request, provide a copy of this Agreement to any person, company, entity or firm.

         

        8.2
        Certain Definitions. The following capitalized terms shall have the meanings assigned to them below:

         

        “Competitive
        Business” means any business that is developing or has developed a cannabinoid agonist for the treatment
        of scleroderma, cystic fibrosis or other inflammatory or fibrotic diseases.

         

        “Employment
        Period” means the period commencing on the Effective Date and continuing through and including the date
        of cessation of the Executive’s employment with the Company.

         

        “Restricted
        Period” means the 12 months from the date of cessation of the Executive’s employment with the Company.

         

        8.3
        Non-Solicitation. During the Employment Period and the Restricted Period, the Executive shall not, directly
        or indirectly, whether on behalf of herself or anyone else: (i) induce or attempt to induce a business associate of the
        Company to refrain from doing business with the Company; (ii) use for her benefit or disclose the name and/or requirements
        of any such business associate to any other person or persons, natural or corporate; or (iii) solicit any of the employees
        of the Company to leave the employ of the Company or hire anyone who is an employee of the Company or has worked for the
        Company during the previous 12 months. The Restricted Period shall be extended by the length of any period during which
        the Executive is in breach of the terms and conditions of this Section 8.3.

         

        8.4
        Separate Covenants. The Executive acknowledges and agrees that the covenants set forth in this Section 8
        are an essential element of this Agreement and the transactions contemplated hereby and that, but for the agreement of
        the Executive to comply with such covenants, the Company would not have entered into this Agreement.




 






    	 	-8-	 



     


    

 


	 	8.5
    Blue Pencil Provision. The parties hereby expressly agree that the duration, scope and geographic area of restriction
    set forth in this Section 8 are reasonable and necessary to protect the legitimate business interests of the Company. If any
    provision of this Agreement should be found by any court of competent jurisdiction to be unenforceable for any reason, including
    but not limited to being too broad as to duration, scope, or area of restriction, then, and in that event, such provision
    will nonetheless remain valid and fully effective, but will be considered to be amended so that the duration, scope, and/or
    area of restriction set forth will be changed to be the maximum duration, scope, or area of restriction, as the case may be,
    that would be found enforceable by such court.
	 	 
	9.

         
	INJUNCTIVE
    RELIEF. The Executive acknowledges that the Company shall not have an adequate remedy in the event that the Executive
    breaches Section 6, 7, 8 or 12 of this Agreement and that the Company will suffer irreparable damage and injury in such event.
    The Executive agrees that the Company, in addition to any other available rights and remedies, shall be entitled to seek an
    injunction (without the necessity of posting a bond) restraining the Executive from committing or continuing any violation
    of Section 6, 7, 8 or 12 of this Agreement.


 


	10.	TERM;
    TERMINATION.


 


	 	10.1	Term.
    Unless earlier terminated in accordance with the provisions of this Section 10, the term of this Agreement shall commence
    on the Effective Date and shall continue thereafter for a period of two (2) years (the “Term”). If the
    Company continues to employ the Executive after the expiration of the Term without a written extension of the term, such employment
    shall continue on an AT-WILL basis and the Company shall have the right to terminate the Executive’s employment for
    any reason or no reason, with or without written notice.


 


	 	10.2	Death.
    Upon the death of the Executive, the Executive’s employment with the Company shall terminate.


 


	 	10.3	Disability.
    If the Executive is unable to perform the essential functions of Employee’s employment with the Company for more than
    twelve weeks (unless a longer period is required by state or federal law), the Company shall have the right to terminate the
    Executive’s employment upon prior written notice.


 


	 	10.4	Termination
    by the Executive. The Executive may terminate this Agreement and her employment hereunder with or without Good Reason
    (as defined below) upon 30 days prior written notice to the Company.


 


	 	10.5	Termination
    by Company. The Company may terminate this Agreement and the Executive’s employment hereunder (i) without Cause
    immediately upon written notice to the Executive or (ii) immediately for Cause.


 




    	 	-9-	 



     


    

 


	 	10.6	Certain
    Definitions. The following capitalized terms shall have the meanings assigned to them below:


 


“Cause”
means: (i) the Executive’s chronic failure to perform those material duties assigned to her pursuant to Section 2 above
to the reasonable satisfaction of the Board after written notice thereof and a reasonable opportunity to respond and/or cure of
not less than 30 days; (ii) the Executive’s gross negligence or misconduct (including but not limited to acts of fraud or
theft or the violation of applicable laws) in connection with the performance of her duties; (iii) the Executive’s material
breach of Section 6, 7 or 8 above; (iv) the Executive’s commission of an act of moral turpitude; (v) the Executive being
dependent on or addicted to alcohol or drugs; or (vi) the Executive’s conviction of or plea of nolo contendere to a felony.


 


“Good
Reason” means the voluntary termination by the Executive within thirty (30) days following: (i) a requirement that
the Executive physically relocates to another office that is more than 75 miles from the office location that the Executive reported
to on the Effective Date; (ii) a reduction in the Executive’s rate of compensation, potential incentive compensation, or
general benefits (other than general changes, in each case, affecting all similarly situated employees to substantially the same
extent); or (iii) a material adverse change in the Executive’s job description or a significant reduction of the scope of
the Executive’s authority or responsibilities.


 


	11.	EFFECT
    OF TERMINATION


 


	 	11.1	Payments
    Upon Termination. In the event that the Executive’s employment with the Company is terminated for any reason,
    the Executive shall have the right to receive (i) the compensation and reimbursable expenses then accrued and/or earned and
    unpaid under Sections 4.1 and 5 of this Agreement through the date of termination, (ii) payment for unused vacation days accrued
    through the date of termination and (iii) any benefits required by the Consolidated Omnibus Budget Reconciliation Act of 1985.


 


	 	11.2	Additional
    Payments.(a) Subject to Sections 11.3 and 11.4, in the event that the Executive’s employment with the Company
    is terminated by the Company without Cause or by the Executive for Good Reason during the Term other than during the Change
    in Control Period (as defined in subsection 11.2(b)), (A) if the Executive then participates in the Company’s medical
    and/or dental plans and the Executive timely elects to continue and maintain group health plan coverage pursuant to COBRA,
    the Company shall reimburse the Executive for the cost of health insurance under COBRA for a period of twelve months; provided,
    however, that if and to the extent that the Company may not provide such COBRA reimbursement without incurring tax
    penalties or violating any requirement of the law, the Company shall use its commercially reasonable best efforts to provide
    substantially similar assistance in an alternative manner, provided that the cost of doing so does not exceed the cost that
    the Company would have incurred had the COBRA reimbursement been provided in the manner described above or cause a violation
    of Section 409A (as defined below), and (B) if the Executive is entitled to a Bonus, subject to the Board’s discretion
    and approval as set forth in Section 4.2 above, the Company shall pay such Bonus in accordance with the terms of the applicable
    plan and on the same basis as other participants in the plan except that the Bonus amount shall be prorated (based on the
    percentage of days the Executive was employed relative to the total number of days in the bonus earning period).



 






    	 	-10-	 



     


    

 


	 	 	(b)
        Subject to Sections 11.3 and 11.4, in the event that the Executive’s employment is terminated by the Company without
        Cause or by the Executive for Good Reason, during the Term and within the 3 months immediately preceding or the 12 months
        immediately following a Change in Control (as defined below) (each, the “Change in Control Period”),
        then in lieu of the payments set forth in subsection 11.2(a) above, the Company shall (A) if the Executive then participates
        in the Company’s medical and/or dental plans and the Executive timely elects to continue and maintain group health
        plan coverage pursuant to COBRA, the Company shall reimburse the Executive for the cost of health insurance under COBRA
        for a period of eighteen (18) months; provided, however, that if and to the extent that the Company may
        not provide such COBRA reimbursement without incurring tax penalties or violating any requirement of the law, the Company
        shall use its commercially reasonable best efforts to provide substantially similar assistance in an alternative manner,
        provided that the cost of doing so does not exceed the cost that the Company would have incurred had the COBRA reimbursement
        been provided in the manner described above or cause a violation of Section 409A (as defined below), (B) pay the current
        year Bonus at the Target Bonus level, which payment shall be made by March 15th of the following calendar year, and (C)
        fully accelerate vesting of all of the Executive’s outstanding stock options, restricted stock and other equity
        incentive awards upon the later of (x) the Change in Control or (y) the Executive’s termination of employment with
        the Company. For avoidance of doubt, if such termination precedes a Change in Control and any payments or benefits have
        commenced pursuant to subsection 11.2(a), such payments or benefits shall be taken into account for purposes of this subsection
        11.2(b).

         

        As
        used in this Agreement, “Change in Control” means (x) a change in ownership of the Company under clause
        (i) below or (y) a change in the ownership of a substantial portion of the assets of the Company under clause (ii) below:

         

        (i)
        Change in the Ownership of the Company. A change in the ownership of the Company shall occur on the date that any
        one person, or more than one person acting as a group (as defined in clause (iii) below), acquires ownership of capital
        stock of the Company that, together with capital stock held by such person or group, constitutes more than 50 percent
        of the total fair market value or total voting power of the capital stock of the Company. However, if any one person or
        more than one person acting as a group, is considered to own more than 50 percent of the total fair market value or total
        voting power of the capital stock of the Company, the acquisition of additional capital stock by the same person or persons
        shall not be considered to be a change in the ownership of the Company. An increase in the percentage of capital stock
        owned by any one person, or persons acting as a group, as a result of a transaction in which the Company acquires capital
        stock in the Company in exchange for property will be treated as an acquisition of stock for purposes of this paragraph.




 






    	 	-11-	 



     


    

 


	 	 	(ii)
        Change in the Ownership of a Substantial Portion of the Company’s Assets. A change in the ownership of a
        substantial portion of the Company’s assets shall occur on the date that any one person, or more than one person
        acting as a group (as defined in clause (iii) below), acquires (or has acquired during the 12-month period ending on the
        date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market
        value equal to or more than 80 percent of the total gross fair market value of all of the assets of the Company immediately
        prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of
        the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with
        such assets. There is no Change in Control under this clause (ii) when there is a transfer to an entity that is controlled
        by the shareholders of the Company immediately after the transfer, as provided below in this clause (ii). A transfer of
        assets by the Company is not treated as a change in the ownership of such assets if the assets are transferred to (a)
        a shareholder of the Company (immediately before the asset transfer) in exchange for or with respect to its capital stock,
        (b) an entity, 50 percent or more of the total value or voting power of which is owned, directly or indirectly, by the
        Company, (c) a person, or more than one person acting as a group, that owns, directly or indirectly, 50 percent or more
        of the total value or voting power of all the outstanding capital stock of the Company, or (d) an entity, at least 50
        percent of the total value or voting power of which is owned, directly or indirectly, by a person described in clause
        (ii)(c) of this paragraph. For purposes of this clause (ii), a person’s status is determined immediately after the
        transfer of the assets.

         

        (iii)
Persons Acting as a Group. For purposes of clauses (i) and (ii) above, persons will not be considered to be acting as a
group solely because they purchase or own capital stock or purchase assets of the Company at the same time. However, persons will
be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or
acquisition of assets or capital stock, or similar business transaction with the Company. If a person, including an entity, owns
stock in both corporations that enter into a merger, consolidation, purchase or acquisition of assets or capital stock, or similar
transaction, such shareholder is considered to be acting as a group with other shareholders in a corporation only with respect
to the ownership in that corporation before the transaction giving rise to the change and not with respect to the ownership interest
in the other corporation. For purposes of this paragraph, the term “corporation” shall have the meaning assigned such
term under Treasury Regulation section 1.280G-1, Q&A-45.




 






    	 	-12-	 



     


    

 


	 	 	(iv)
    Each of clauses (i) through (iii) above shall be construed and interpreted consistent with the requirements of Section 409A
    and any Treasury Regulations or other guidance issued thereunder.


 


	 	11.3	Release
    Agreement. In order to receive the payments and benefits set forth in Sections 8.1 and 11.2, as applicable (collectively
    referred to herein as the “Severance Payments”), the Executive must timely execute (and not revoke)
    a separation agreement and general release (the “Release Agreement”) in a customary form as is determined
    to be reasonably necessary by the Company in its good faith and reasonable discretion and which form shall include a non-compete
    provision. If the Executive is eligible for Severance Payments pursuant to Sections 8.1 and 11.2, the Company will deliver
    the Release Agreement to the Executive within seven (7) calendar days following the date of termination of employment. The
    Severance Payments are subject to the Executive’s execution and delivery of such Release Agreement within 45 days of
    the Executive’s receipt of the Release Agreement and the Executive’s non-revocation of such Release Agreement.


 


	 	11.4	Post-Termination
    Breach. Notwithstanding anything to the contrary contained in this Agreement, the Company’s obligation to provide
    the Severance Payments will immediately cease if the Executive breaches any of the provisions of Sections 6, 7 or 8, the Release
    Agreement or any other Agreement the Executive has with the Company.


 


	 	11.5	No
    Other Payments or Benefits. The Executive acknowledges and agrees that upon the termination of her employment, no
    other benefits, compensation or remuneration of any kind is owed by the Company to the Executive other than as set forth in
    Sections 8.1 and 11 or as set forth in the Option Agreements.


 


	 	11.6	Survival.
    Notwithstanding anything to the contrary set forth herein, Sections 6, 7, 8, 9 and 11-19 of this Agreement and any remedies
    for the breach thereof, shall survive the termination of this Agreement under the terms hereof. Termination of this Agreement
    shall not relieve or release either party from any rights, liabilities or obligations which it/she has accrued prior to the
    effective date of such termination.


 




    	 	-13-	 



     


    

 


	12.	RETURN
    OF COMPANY PROPERTY; EXIT INTERVIEW. Upon termination of the Executive’s employment with the Company for any
    reason, the Executive will promptly:


 


	 	(a)	Deliver
    to the Company all documents and other tangible media in the Executive’s possession or control that evidence, contain
    or reflect (A) Confidential Information or (B) Work Product, in each case whether prepared by the Executive or otherwise coming
    into the Executive’s possession or control;


 


	 	(b)	Destroy
    any intangible materials that evidence, contain or reflect Confidential Information or Work Product on equipment or media
    not owned by the Company, unless otherwise directed by the Company; and


 


	 	(c)	Return
    to the Company all equipment, files, software programs and other personal property belonging to the Company. 


 


Upon
termination of the Executive’s employment with the Company for any reason, the Executive will attend an exit interview with
a representative of the Company to review the Executive’s continuing obligations under this Agreement.


 


	13.	ENTIRE
    AGREEMENT. This Agreement constitutes the entire agreement between the parties with respect to the subject matter
    hereof and supersedes all contemporaneous and prior agreements and understandings between them as to such subject matter.
    Not in limitation of the foregoing, this Agreement supersedes the Prior Employment Agreement. Except as otherwise expressly
    provided herein, this Agreement may not be amended except by an instrument in writing executed by the Company and the Executive.
    Subject to the other provisions of this Agreement, any subsequent change or changes in the Executive’s duties, salary,
    or compensation will not affect the validity or scope of this Agreement, including the validity or scope of Section 8. 


 


	14.	ASSIGNMENT.
    The Executive shall not be permitted to assign this Agreement or any rights or obligations hereunder without the prior written
    consent of the Company. 


 


	15.	GOVERNING
    LAW; JURISDICTION. This Agreement shall be construed and enforced in accordance with and governed by the laws of the
    Commonwealth of Massachusetts without giving effect to the principles of conflicts of laws thereof. The parties hereby consent
    and submit to the exclusive jurisdiction and venue of the courts located in Suffolk County, Massachusetts in connection with
    any actions or proceedings brought against either of them (or each of them) arising out of or relating to this Agreement.


 


	16.	MISCELLANEOUS.
    No waiver by either party of any term or condition of this Agreement, whether by conduct or otherwise, in any one or more
    instance, shall be deemed a continuing waiver of any such term or condition, or a waiver of any other term or condition of
    this Agreement. Headings set forth in this Agreement are solely for the convenience of the parties and have no legal effect.
    If any provision of this Agreement shall be found to be invalid by any court having competent jurisdiction, the invalidity
    of such provision shall not affect the validity of the remaining provisions hereof. This Agreement shall be (i) binding upon,
    and will inure to the benefit of, the parties and their permitted
    respective successors and assigns, (ii) construed without presumption of any rule requiring construction to be made against
    the party causing it to be drafted and (iii) executed in any number of counterparts, each of which will for all purposes be
    deemed to be an original, and all of which are identical.


 




    	 	-14-	 



     


    

 


	17.	TAX
    WITHHOLDING. The Company or other payor is authorized to withhold from any benefit provided or payment due hereunder,
    the amount of withholding taxes due any federal, state or local authority in respect of such benefit or payment and to take
    such other action as may be necessary in the opinion of the Board to satisfy all obligations for the payment of such withholding
    taxes. The Executive will be solely responsible for all taxes assessed against her with respect to the compensation and benefits
    described in this Agreement, other than typical employer-paid taxes such as FICA, and the Company makes no representations
    as to the tax treatment of such compensation and benefits. 


 


	18.	SECTION
    409A COMPLIANCE. All payments under this Agreement are intended to comply with or be exempt from the requirements
    of Section 409A of the Code and regulations promulgated thereunder (“Section 409A”). As used in this Agreement,
    the “Code” means the Internal Revenue Code of 1986, as amended. To the extent permitted under applicable
    regulations and/or other guidance of general applicability issued pursuant to Section 409A, the Company reserves the right
    to modify this Agreement to conform with any or all relevant provisions regarding compensation and/or benefits so that such
    compensation and benefits are exempt from the provisions of 409A and/or otherwise comply with such provisions so as to avoid
    the tax consequences set forth in Section 409A and to assure that no payment or benefit shall be subject to an “additional
    tax” under Section 409A. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section
    409A, or to the extent any provision in this Agreement must be modified to comply with Section 409A, such provision shall
    be read in such a manner so that no payment due to the Executive shall be subject to an “additional tax” within
    the meaning of Section 409A(a)(1)(B) of the Code. If necessary to comply with the restriction in Section 409A(a)(2)(B) of
    the Code concerning payments to “specified employees,” any payment on account of the Executive’s separation
    from service that would otherwise be due hereunder within six (6) months after such separation shall be delayed until the
    first business day of the seventh month following the date of termination of employment and the first such payment shall include
    the cumulative amount of any payments (without interest) that would have been paid prior to such date if not for such restriction.
    Each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section 409A. In no
    event may the Executive, directly or indirectly, designate the calendar year of payment. All reimbursements provided under
    this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable,
    the requirement that (i) any reimbursement is for expenses incurred during the Executive’s lifetime (or during a shorter
    period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year
    may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible
    expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and
    (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit. Notwithstanding anything contained
    herein to the contrary, the
    Executive shall not be considered to have terminated employment with the Company for purposes of Section 11.2 unless the Executive
    would be considered to have incurred a “termination of employment” from the Company within the meaning of Treasury
    Regulation §1.409A-1(h)(1)(ii). In no event whatsoever shall the Company be liable for any additional tax, interest or
    penalty that may be imposed on the Executive by Section 409A or damages for failing to comply with Section 409A.


 




    	 	-15-	 



     


    

 


	19.	280G
    MODIFIED CUTBACK.


 


	 	(a)	If
    any payment, benefit or distribution of any type to or for the benefit of the Executive, whether paid or payable, provided
    or to be provided, or distributed or distributable pursuant to the terms of this Agreement or otherwise (collectively, the
    “Parachute Payments”) would subject the Executive to the excise tax imposed under Section 4999 of the Code
    (the “Excise Tax”), the Parachute Payments shall be reduced so that the maximum amount of the Parachute
    Payments (after reduction) shall be one dollar ($1.00) less than the amount which would cause the Parachute Payments to be
    subject to the Excise Tax; provided that the Parachute Payments shall only be reduced to the extent the after-tax value of
    amounts received by the Executive after application of the above reduction would exceed the after-tax value of the amounts
    received without application of such reduction. For this purpose, the after-tax value of an amount shall be determined taking
    into account all federal, state, and local income, employment and excise taxes applicable to such amount. Unless the Executive
    shall have given prior written notice to the Company to effectuate a reduction in the Parachute Payments if such a reduction
    is required, which notice shall be consistent with the requirements of Section 409A to avoid the imputation of any tax, penalty
    or interest thereunder, then the Company shall reduce or eliminate the Parachute Payments by first reducing or eliminating
    accelerated vesting of stock options or similar awards, then reducing or eliminating any cash payments (with the payments
    to be made furthest in the future being reduced first), then by reducing or eliminating any other remaining Parachute Payments;
    provided, that no such reduction or elimination shall apply to any non-qualified deferred compensation amounts (within the
    meaning of Section 409A) to the extent such reduction or elimination would accelerate or defer the timing of such payment
    in a manner that does not comply with Section 409A.


 


	 	(b)	An
    initial determination as to whether (x) any of the Parachute Payments received by the Executive in connection with the occurrence
    of a change in the ownership or control of the Company or in the ownership of a substantial portion of the assets of the Company
    shall be subject to the Excise Tax, and (y) the amount of any reduction, if any, that may be required pursuant to the previous
    paragraph, shall be made by an independent accounting firm selected by the Company (the “Accounting Firm”)
    prior to the consummation of such change in the ownership or effective
    control of the Company or in the ownership of a substantial portion of the assets of the Company. The Executive shall be furnished
    with notice of all determinations made as to the Excise Tax payable with respect to the Executive’s Parachute Payments,
    together with the related calculations of the Accounting Firm, promptly after such determinations and calculations have been
    received by the Company.


 




    	 	-16-	 



     


    

 


	 	(c)	For
    purposes of this Section 19, (i) no portion of the Parachute Payments the receipt or enjoyment of which the Executive shall
    have effectively waived in writing prior to the date of payment of the Parachute Payments shall be taken into account; (ii)
    no portion of the Parachute Payments shall be taken into account which in the opinion of the Accounting Firm does not constitute
    a “parachute payment” within the meaning of Section 280G(b)(2) of the Code; (iii) the Parachute Payments shall
    be reduced only to the extent necessary so that the Parachute Payments (other than those referred to in the immediately preceding
    clause (i) or (ii)) in their entirety constitute reasonable compensation for services actually rendered within the meaning
    of Section 280G(b)(4) of the Code or are otherwise not subject to disallowance as deductions, in the opinion of the auditor
    or tax counsel referred to in such clause (ii); and (iv) the value of any non-cash benefit or any deferred payment or benefit
    included in the Parachute Payments shall be determined by the Company’s independent auditors based on Sections 280G
    and 4999 of the Code and the regulations for applying those sections of the Code, or on substantial authority within the meaning
    of Section 6662 of the Code.


 




    	 	-17-	 



     


    

 


IN
WITNESS WHEREOF, the undersigned have executed this Employment Agreement as of the Effective Date.


 


	 	Corbus
    Pharmaceuticals Holdings, Inc.
	 	 	 
	 	By:	                                              
	 	Name:	Yuval
    Cohen, Ph.D.
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	By:	
	 	Name:	Barbara
    White
	 	Address:	[*]


 




    	 	-18-	 



     


    

 


Schedule
A


 


Executive
Statement Regarding Prior Inventions


 


Except
as set forth below, the Executive acknowledges that at this time she does not have any right, title or interest in or to any Prior
Inventions (as defined in Section 7.8 of this Agreement) except those (if any) listed below:


 


[List
any applicable Prior Inventions or write “None”.] 


 


[If
you need more space please attach a separate continuation sheet]


 


The
Executive certifies that the foregoing is true, accurate and complete.


 


	The
    Executive’s Name:		 
	 	 	 
	Date:	 	 
	 	 	 
	Signature:		 


 




    	 	-19-